Ignite Creation Date:
2024-05-06 @ 9:43 AM
Last Modification Date:
2024-10-26 @ 12:18 PM
Study NCT ID:
NCT03050398
Status:
TERMINATED
Last Update Posted:
2020-05-28
First Post:
2017-02-06
Brief Title:
A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK46 TherapyLEE011Ribociclib
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Breast Cancer |
Keywords:
| Name | View |
|---|---|
| Men | View |
| HR-positive | View |
| HER2-negative | View |
| Advanced breast cancer | View |
| LEE011 | View |
| ribociclib | View |
| letrozole | View |
| femara | View |
| CDK | View |
| CDK4 | View |
| CDK6 | View |
| CDK46 | View |
| CDK46 inhibitor | View |
| Phase III | View |
| Phase IIIb | View |
| ER-positive | View |
| PR-positive | View |
| Postmenopausal | View |
| Premenopausal | View |